ISEE - IVERIC bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

IVERIC bio, Inc.

One Penn Plaza
19th Floor Suite 3520
New York, NY 10119
United States
212-845-8200
http://ivericbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees34

Key Executives

NameTitlePayExercisedYear Born
Dr. David R. GuyerExec. Chairman769.25kN/A1960
Mr. Glenn P. Sblendorio M.B.A.CEO, Pres & Director1.09MN/A1956
Mr. David F. CarrollSr. VP, CFO & Treasurer536.23kN/A1966
Mr. Keith Westby M.B.A.Sr. VP & COO495.92kN/A1975
Dr. Samir C. Patel M.D.Co-Founder and ConsultantN/AN/A1961
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.

Corporate Governance

IVERIC bio, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.